Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin

Thrombosis Research

Volumn 136, Issue 6, 2015, Pages 1273-1279

  Rousseau, Aurélie ^a   Van Dreden, Patrick ^b   Mbemba, Elisabeth ^a   Elalamy, Ismail ^a,c   Larsen, Annette ^a   Gerotziafas, Grigoris T ^a,c  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b Research and Development   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Anticoagulant; Apixaban; Cancer; Fondaparinux; Low molecular weight heparin; NOAC; Thrombin generation

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; FONDAPARINUX; THROMBIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; POLYSACCHARIDE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULATION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; IC50; MCF 7 CELL LINE; MICROSCOPY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; THROMBOCYTE RICH PLASMA; BREAST TUMOR; CHEMISTRY; COMPLICATION; CYTOLOGY; FEMALE; IMMUNOLOGY; MCF-7 CELL LINE; PANCREAS TUMOR; THROMBOCYTE; THROMBOSIS; TUMOR CELL LINE;

ANTICOAGULANTS; BLOOD PLATELETS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENOXAPARIN; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; PANCREATIC NEOPLASMS; POLYSACCHARIDES; PYRAZOLES; PYRIDONES; THROMBIN; THROMBOSIS;

EID: 84949256059     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.08.009     Document Type: Article

References (33)

1. S.R. Kahn, W. Lim, A.S. Dunn, M. Cushman, F. Dentali, E.A. Akl, D.J. Cook, A.A. Balekian, R.C. Klein, H. Le, S. Schulman, M.H. Murad, and American College of Chest Physicians Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 Suppl. 2 2012 e195S e226S
2. A.N. Nicolaides, J. Fareed, A.K. Kakkar, A.J. Comerota, S.Z. Goldhaber, R. Hull, K. Myers, M. Samama, J. Fletcher, E. Kalodiki, D. Bergqvist, J. Bonnar, J.A. Caprini, C. Carter, J. Conard, B. Eklof, I. Elalamy, G. Gerotziafas, G. Geroulakos, A. Giannoukas, and et al. Prevention and treatment of venous thromboembolism - International Consensus Statement Int. Angiol. 32 2013 111 260
3. D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, B. Brenner, D. Brilhante, A. Falanga, G.T. Gerotzafias, N. Haim, A.K. Kakkar, A.A. Khorana, R. Lecumberri, M. Mandala, M. Marty, M. Monreal, S.A. Mousa, S. Noble, I. Pabinger, P. Prandoni, and et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer J. Thromb. Haemost. 11 2013 56 70
4. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, S.Z. Goldhaber, M.E. Nelson, P.S. Wells, M.K. Gould, F. Dentali, M. Crowther, S.R. Kahn, and American College of Chest Physicians Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 Suppl. 2 2012 e419S e494S
5. N.M. Kuderer, and G.H. Lyman Guidelines for treatment and prevention of venous thromboembolism among patients with cancer Thromb. Res. 133 Suppl. 2 2014 S122 S127
6. A.Y. Lee Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants Hematol. Am. Soc. Hematol. Educ. Programs 2010 2010 144 149
7. H.C. Hemker, and S. Béguin The mode of action of heparins in vitro and in vivo Adv. Exp. Med. Biol. 313 1992 221 230
8. M. Monreal, C. Falgá, M. Valdés, C. Suárez, F. Gabriel, C. Tolosa, and J. Montes Riete investigators: fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry J. Thromb. Haemost. 4 2006 1950 1956
9. D. Imberti, G. Agnelli, W. Ageno, M. Moia, G. Palareti, R. Pistelli, R. Rossi, M. Verso, and M.A.S.T.E.R. Investigators Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry Haematologica 93 2008 273 278
10. J. Douketis, A.D. Bell, J. Eikelboom, and A. Liew Approach to the new oral anticoagulants in family practice: part 1: comparing the options Can. Fam. Physician 60 2014 989 995
11. A. Pudusseri, R. Shameem, and A.C. Spyropoulos A new paradigm shift in antithrombotic therapy Front. Pharmacol. 4 2013 133
12. M.N. Levine, C. Gu, H.A. Liebman, C.P. Escalante, S. Solymoss, D. Deitchman, L. Ramirez, and J. Julian A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer J. Thromb. Haemost. 10 2012 807 814
13. G.T. Gerotziafas, I. Mahé, and I. Elalamy New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients Ther. Clin. Risk Manag. 10 2014 423 436
14. G.T. Gerotziafas, V. Galea, E. Mbemba, A. Khaterchi, M. Sassi, H. Bacouche, C. Prengel, P. van Dreden, M. Hatmi, J.F. Bernaudin, and I. Elalamy Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7 Thromb. Res. 129 2012 779 786
15. G.T. Gerotziafas, V. Galea, E. Mbemba, M. Sassi, M.P. Roman, A. Khaterchi, P. Van Dreden, M. Japcowitz, J.P. Lotz, J.F. Bernaudin, J. Fareed, M. Hatmi, and I. Elalamy Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3 Curr. Vasc. Pharmacol. 12 2014 893 902
16. H.C. Hemker, G.M. Willems, and S. Beguin A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes Thromb. Haemost. 56 1986 9 17
17. G.T. Gerotziafas, F. Depasse, J. Busson, L. Leflem, I. Elalamy, and M.M. Samama Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay Thromb. J. 3 2005 16
18. H.M. Spronk, A.W. Dielis, E. De Smedt, R. van Oerle, D. Fens, M.H. Prins, K. Hamulyák, and H. ten Cate Assessment of thrombin generation II: validation of the calibrated automated thrombogram in platelet-poor plasma in a clinical laboratory Thromb. Haemost. 100 2008 362 364
19. Y. Dargaud, R. Luddington, E. Gray, T. Lecompte, T. Siegemund, T. Baglin, J. Hogwood, V. Regnault, A. Siegemund, and C. Negrier Standardisation of thrombin generation test - which reference plasma for TGT? An international multicentre study Thromb. Res. 125 2010 353 356
20. J. Fareed, D.A. Hoppensteadt, and R.L. Bick An update on heparins at the beginning of the new millennium Semin. Thromb. Hemost. 26 Suppl. 1 2000 5 21
21. T.W. Barrowcliffe, S.J. Havercroft, G. Kemball-Cook, and U. Lindahl The effect of Ca2 +, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides Biochem. J. 243 1987 31 37
22. H. Speijer, D. Billy, G. Willems, H.C. Hemker, and T. Lindhout Inhibition of prothrombinase by antithrombin-heparin at a macroscopic surface Thromb. Haemost. 73 1995 648 653
23. J.P. Herault, A. Bernat, A.M. Pflieger, J.C. Lormeau, and J.M. Herbert Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase J. Pharmacol. Exp. Ther. 283 1997 16 22
24. G. Jourdi, V. Siguret, A.C. Martin, J.L. Golmard, A. Godier, C.M. Samama, P. Gaussem, I. Gouin-Thibault, and B. Le Bonniec Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban Thromb. Haemost. 114 2015 78 86
25. J.M. Luettgen, R.M. Knabb, K. He, D.J. Pinto, and A.R. Rendina Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma J. Enzyme Inhib. Med. Chem. 26 2011 514 526
26. L. Lian, L. Wei, L. Zhen-Yu, Y.X. Mao, Y.T. Zhang, Y.M. Zhao, K. Chen, W.M. Duan, and M. Tao Inhibition of MCF7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs Oncol. Lett. 5 2013 675 680
27. L. Zuckerman, J.M. Ramstack, J.P. Vagher, J.A. Caprini, and L.F. Mockros Neutralization of heparin by cellular blood elements Thromb. Res. 7 1975 149 159
28. H. ten Cate, and A. Falanga Overview of the postulated mechanisms linking cancer and thrombosis Pathophysiol. Haemost. Thromb. 36 2008 122 130
29. M. Marchetti, E. Diani, H. ten Cate, and A. Falanga Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography Haematologica 97 2012 1173 1180
30. M. Matan, E. Axelman, B. Brenner, and Y. Nadir Heparanase procoagulant activity is elevated in women using oral contraceptives Hum. Reprod. 28 2013 2372 2380
31. A.D. Theocharis, S.S. Skandalis, G.N. Tzanakakis, and N.K. Karamanos Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting FEBS J. 277 2010 3904 3923
32. U. Barash, V. Cohen-Kaplan, I. Dowek, R.D. Sanderson, N. Ilan, and I. Vlodavsky Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis FEBS J. 277 2010 3890 3903
33. J. Fareed, J.M. Walenga, D. Hoppensteadt, X. Huan, and A. Racanelli Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins Haemostasis 18 Suppl. 3 1988 3 15